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Summary. Endometrial stromal sarcoma (ESS) is uncommon uterine malignant tumor and makes approximately 0.2 % 
of all gynecological malignancies. It is the rarest tumor in the group of mesenchymal uterine tumors. Diagnosis may be 
difficult, since differentiation between several soft-tissue uterine neoplasms such as highly cellular leiomyoma, cellular 
endometrial polyp, low-grade Mullerian carcinosarcoma and adenomyosis is tricky. Treatment is surgical, hysterectomy 
and bilateral adnexectomy is obligatory, the role of lymphadenectomy is still controversial. Since ESS is hormone de-
pendent tumor, hormone therapy as adjuvant therapy can be taken into consideration. In this article we present a 57-year-
old patient, clinically asymptomatic, with peculiar TV ultrasound feature, and ESS diagnosed on patho-histologically 
after operation due to presumed benign diagnosis.
Introduction
Group of mesenchymal uterine tumors includes differ-
ent types of sarcomas (leiomyosarcoma, endometrial 
stromal sarcoma) and Mullerian mixed malignant tumors 
(carcinosarcoma). They are histologically and biologi-
cally different. Given the rarity of these tumors, they rep-
resent “terra incognita” in corpus uteri malignancies. 
Their many unclear features, and highly aggressive be-
havior challenge pathologists and frustrate physicians.
Epidemiology
Sarcomas represent 4–9 % of all uterine invasive tu-
mors with annual incidence of 1.6–3.3 cases in 100 000 
women/year (1,2). Most common histological variety is 
made up of malignant Mullerian mixed tumors (50%), 
followed by leiomyosarcomas (30%), and by endome-
trial stromal sarcomas (10–15%) with incidence respec-
tively 0.82 (malignant Mullerian mixed tumors) 0.64 
(leiomyosarcomas) and 0.19 (endometrial stromal sar-
comas) per 100000 women/year. Mean age of patients 
at the time of detection varies depending on histological 
type. Incidence of leiomyosarcomas increases with the 
age, with a peak of incidence around the age of 52 years 
(mean age 48–55) and then incidence declines in older 
age. Mean age of onset of carcinosarcoma is 62–67 
years. Endometrial stromal sarcoma (ESS) intends to 
appear in younger age compared with other sarcomas 
and in more than 50% of patients appears before meno-
pauses (mean age 41–63) (1–3). In this article we deal 
with this malignant tumor.
Pathogenesis, biology and cytogenetics
The pathogenesis of ESS is unknown, but as ESS are 
hormone sensitive tumors, a state of high estrogen could 
act as a growth stimulus. Exposure to tamoxifen, unop-
posed estrogens, and conditions such as polycystic dis-
ease of ovary is implicated in occurrence of this tumor. 
Increased incidence of ESS is noticed in women of 
black race (4). The origin and biology of stromal sarco-
mas are poorly understood. There is a relation between 
chromosomal aberrations and endometrial sarcomas. 
Specific translocation t (7;17) (p15; q21) was described 
in most of the ESS (12). Chromosomal deletion on 7p 
was the most common finding (55.6%) in ESS and may 
play a role in tumor development and progression (13). 
These tumors are diploid with a low S-phase fraction 
(11). An important key to improve the knowledge of tu-
morigenesis of ESS is identification and characteriza-
tion of genes that are mutated in this rare tumor and that 
are responsible for altered cell cycle. Recently, some 
new, sophisticated techniques such as cDNA arrays to-
gether with PCR (Polymerase chain reaction is a tech-
nique to make many copies of a specific DNA region in 
vitro) and immunohistochemistry enabled us to identify 
more than 300 genes mutated in stromal endometrial 
sarcoma. Among most significantly downregulated 
genes where those of SFRP proteins, protein 4 (Secret-
ed frizzled–related protein4/ SFRP4). SFRP4 is a mem-
ber of the SFRP family that contains a cysteine-rich 
domain homologous to the putative (supposed, as-
sumed) Wnt-binding site of Frizzled proteins. SFRP act 
as soluble modulators of Wnt-signalling (Wnt – acro-
nym in the field of genetics that stands for “Wingless/
Integrated”). The Wnt-signallig pathways are a group of 
signal transduction pathways which begin with proteins 
that pass signals into a cell through cell surface recep-
tors. Wnt-signalling is a complex cascade of heteroge-
neous molecules that play an important role in develop-
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there is evidence that mutations of Wnt–signaling is 
responsible for tumorigenesis in different organs. There 
is a proof that SFRP4 plays a role in the sequence of 
Wnt-signallig through beta-catenin, one multifunction-
al protein that is fundamental for tumor suppressing. 
Recently it has been demonstrated that expression of 
beta-catenin is adjusted in opposite way to SFRP4 and 
is increased both in ESS and UES. According to this 
newly discovered fact it has been suggested that SFRP4 
could be a possible onco-suppressor involved in dereg-
ulation (mis regulation) of Wnt sequence and in patho-
genesis of ESS and UES (12,13,15).
Pathohistology
ESS where, for a long time, subdivided in high grade 
and low grade, in relation to number of mitosis (6,9). 
Subsequently the traditional classification of ESS has 
been replaced, and high-grade tumors without recogniz-
able evidence of a definite endometrial stromal pheno-
type are now termed undifferentiated endometrial sar-
comas (UES) instead of high-grade ESS. In the latest 
2003. WHO classification, endometrial stromal tumors 
are divided into:
a) Endometrial stromal nodule (ESN)
– well circumscribed, soft, non-encapsulated neo-
plasm – tan to yellow cut surface – M/E non-infiltrating 
border – lobulated or finger like projections into the 
myometrium that are less than 3 mm long and less than 
3 in number
b)  Low-grade endometrial stromal sarcoma 
(LGESS or ESS)
– irregular nodular growth involving the endometri-
um with varying degrees of permeation to myometrium 
including warm like plugs of tumor that fill the myome-
trial veins (often extending to parametria veins) – pro-
liferation of uniformly small cells closely resembling 
those of endometrial stroma in the proliferative stage. 
The cells have scanty cytoplasm, oval to round nuclei 
and unnoticeable (unremarkable) nucleoli – significant 
atypia and pleomorphism are absent – mitotic activity is 
usually less than 5/10 high power fields
c)  Undifferentiated endometrial  
or uterine sarcoma (UES)
– polypoid, fleshy, grey to yellow endometrial masses 
and often show prominent hemorrhage and necrosis – 
marked cellular atypia and abundant mitotic activity, 
often including atypical forms – they lack the typical 
growth pattern and vascularity of low-grade ESS and 
displace the myometrium in contrast to the infiltrative 
pattern of low-grade ESS – they resemble the sarcoma-
tous component of carcinosarcoma
In this classification the differentiation between low-
grade and undifferentiated tumors is not made on mi-
totic count but based on nuclear pleomorphism and ne-
crosis (11,15,66). Since myometrial and vascular inva-
sion are the two features that help us to differentiate 
ESS from ESN and the UES resembles the sarcomatous 
component of carcinosarcoma (UES represents a high-
grade sarcoma that lacks specific differentiation and 
bears no histological resemblance to endometrial stro-
ma), extensive sampling of the tissues is required for 
confirmation of diagnosis (5,6). Macroscopically EES 
is presented like a single, well defined intramural mass 
with or without polypoid component, or more frequent 
like one marked adenomyosis which invades myome-
trium and extends at serosa in approximately half of 
cases. Surface is yellow-brownish, on cut grayish. Le-
sion has fluffy consistence unlike a classic leiomyoma, 
and doesn’t present protuberant, bulgy aspect character-
istic for myoma. Rarely there are myxoid or cystic as-
pects or focal hemorrhages and necrosis (Fig 1).
Diagnosis
Differentiation between several soft-tissue neoplasms 
demonstrating arborizing vasculature (vascularization) 
such as highly cellular leiomyoma, cellular endometrial 
polyp, low-grade Mullerian adenosarcoma and ade no-
myosis the diagnosis of ESS may become more difficult.
Clinical presentation
The most common symptom of ESS is abnormal 
uterine bleeding and occurs in about 90% of women. 
Uterine enlargement shows up to 70 % of cases. ESS 
sometimes present with pelvic pain and dysmenorrhea. 
An asymptomatic ESS occurs in 25% individuals. 
About 30 to 50% of the ESS has extra uterine spread at 
the time of the diagnosis (16,17).
Immunohistochemistry
CD10 is a cell-surface neutral endopeptidase, seen 
originally on immature lymphoid cells. Recently, CD10 
expression has been shown in several nonhematopoietic 
neoplasm, including endometrial stromal sarcomas 
Figure 1. Makrocroscopic image of endometrial stromal sarcoma
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(20). Immunomarkers such as desmin, h-caldesmon, 
oxytocin receptors, CD10, and inhibin are useful in dis-
tinguishing cellular leiomyoma. They express h-caldes-
mon, desmin, and oxytocin receptors while CD10 and 
inhibin expression is a feature of ESS (21–23). ESS is 
almost always positive for both estrogen and progester-
one receptors.
Hysteroscopy/curettage
Although ESS arises from the stroma (connective tis-
sue) of the endometrium the main tumor mass is almost 
always in myometrium, most ESS involve the endome-
trium as well, and uterine curettage may be helpful in 
preoperative diagnosis (16,17). However, when the le-
sion is completely within the myometrium, the scrap-
ings may not be helpful. In addition, hysteroscopic fea-
tures of uterine sarcomas are often like those of endo-
metrial polyps or submucosal myomas. Due to the great 
similarity of ESS with normal endometrium (in prolif-
erative stage), it may be impossible to diagnose it with 
certainty on curettage fragments, and the definitive di-
agnosis can be made only on a hysterectomy specimen.
Imaging diagnostic  
(radiology and ultrasound)
Ultrasound imaging is not of great use, it is unreli-
able, and can lead to the incorrect diagnosis of adeno-
myosis or uterine leiomyoma. Trans vaginal color Dop-
pler shows low impedance flow compared to other be-
nign tumors. Magnetic resonance imaging can be useful 
for a preoperative diagnosis. The important imaging 
feature that suggests ESS is the presence of bands (for-
mations) of low-signal intensity within the area of myo-
metrial invasion (18).
Therapy
The low incidence is a major limitation for setting big 
trials. Currently, no evidence supports a defined treat-
ment, and the best management appears to be surgical, 
although hormone and radiotherapy are represented too.
Surgery
There are no reliable randomized studies related to 
chirurgical treatment od ESS, but in general, the key-
stone is hysterectomy. Some authors take the ovarian 
preservation into consideration, since this tumor attacks 
younger population – cases under the age of 30 are de-
scribed (30,35,39). In post menopause, standard treat-
ment remains hysterectomy and bilateral adnexectomy. 
The role of lymphadenectomy remains limited because 
the great percentage of ESS patients with none metasta-
sis in lymph nodes either way develop recurrences (27–
29,31–34,36–39).
Hormone therapy
Hormone therapy is expected to be effective in ESS 
because of estrogen and progesterone receptors in it. 
Hormones include megestrol/ medroxyprogesterone, 
gonadotropin releasing hormone (GnRH) analogues, 
and aromatase inhibitors (40). The mechanism of action 
of progestins is to bind progesterone receptors and to 
slow down regulate gene transcription leading to de-
creased endometrial gland and stromal proliferation. 
GnRH agonists slows down regulate GnRH receptors in 
the anterior pituitary gland, leading to a hypoestrogenic 
state. Estrogen deprivation is most specifically achieved 
using inhibitors that block the last stage in the biosyn-
thetic sequence, that is, the conversion of androgens to 
estrogens by the aromatase enzyme. The new genera-
tion aromatase inhibitors such as letrozole, when given 
orally, inhibits peripheral aromatase and causes a 
marked reduction in circulating estrogens. ESS shows 
expression of aromatase enzyme and aromatase inhibi-
tors such as letrozole and anastrozole can be used as 
adjuvant treatment (33,51,52,54).
The literature data related to adjuvant hormone thera-
py for EES are rare and are based on small number of 
patients. Particularly there are no studies of stage III, to 
support use of hormones in therapy. Schwartz et al. sug-
gested use of progesterone (for example megestrol ace-
tate, in dosage 160 mg /day) at least for 24 months in 
patients with complete resection of tumor (33).
Radiotherapy
RT in the form of brachytherapy with or without pel-
vic radiation can be used as adjuvant therapy. This will 
be useful for control of local recurrences but with lim-
ited effect on long term survival (28,29,53). It is not 
recommended routinely in FIGO stage-I and stage-II 
disease. However, radiotherapy can be considered for 
advanced or recurrent cases (28,29,53).
Chemotherapy should be reserved for patients with 
hormone not-responsive tumor.
Prognosis
Clinical factors such as age, race, parity, menopausal 
status and pathological factors including tumor size, tu-
mor stage, nuclear atypia, mitotic activity, tumor necro-
sis, lymph vascular space invasion, DNA ploidy prolif-
erative activity, and expression of hormone receptors, 
are to be taken into consideration for prognosis. Prog-
nostic factors for poor survival are: high age (older pa-
tients) – age more than 50 years, black race, advanced 
stage, lack of primary surgery, nodal metastasis, high 
mitotic count – more than 5 per 10 high-power fields, 
CD10 negative or low expression and lack of estrogen 
and progesterone receptors (25,26). Tumor classifica-
tion is essential for prognosis (16,17,19). If properly 
classified (since ESS represents a separate clinical enti-
ty and has a way much better life expectancy than other 
sarcomas), the most important prognostic factor is the 
stage of the disease at the time of detection.
2009. FIGO staging for uterine sarcomas (Leiomyo-
sarcomas and ESS):
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Stage I (Tumor limited to the uterus): IA Less than or 
equal to 5 cm; IB More than 5 cm
Stage II (Tumor extends beyond the uterus, within 
the pelvis): IIA Adnexal involvement; IIB Involvement 
of other pelvic tissues
Stage III (Tumor invades abdominal tissues, not just 
protruding into the abdomen): IIIA One site; IIIB More 
than one site; IIIC Metastases to pelvic and/or paraaor-
tic lymph nodes
Stage IV: IVA Tumor invades bladder and/or rectum; 
IVB Distant metastases
At FIGO stage I, the 5-year survival rate for ESS is 
54% to nearly 100%. At stage-II it is 30%. For advanced 
disease (stage III and IV) the survival is only 11%. As 
these tumors are indolent (lazy) and have a tendency for 
late recurrence, long-term follow up is essential. It shall 
be once in 3 months for the first year after primary treat-
ment. Than half-yearly for next 4 years. Thereafter an-
nual follow up is sufficient (25–27,60).
Recurrent disease
Recurrences develop in one-third to one-half of pa-
tients with ESS and are usually limited to the pelvis and 
lower genital tract. Distant metastasis to lungs and su-
perior abdominal cavity may occur after several years, 
even more than 20 years. Metastases in brain are rare 
(54,55). A growth stimulus by estrogens on residual tu-
mor cells may contribute to recurrence. After oophorec-
tomy, estrogens produced by peripheral tissues or exog-
enous administration in the form of hormone replace-
ment therapy may be a reason for recurrences (56).
There is no standard therapy for patients with recur-
rent disease. Recurrent ESS has been treated with hor-
mone therapy, radiation, surgical re-excision, or a com-
bination of these modalities (56,57).
Case Report
A 57 years old woman appeared in our Department, 
send by her gynecologist in primary health care, for pe-
culiar (problematic) ultrasound formation inside myo-
metrium. She had no symptoms, nor mayor gynecologi-
cal troubles so far. She delivered two healthy children. 
Her menstrual cycles were irregular all her life. She 
said: „I never knew when menstruation will come, and 
when it came, I never knew when it will stop “. Patient 
was premenopausal, her last “irregular” bleeding 
stopped 7 days before first consultation.
At bimanual examination an enlarged uterus and nor-
mal ovaries were found.
When transvaginal sonography was performed in our 
department, within an enlarged uterus (9.1 x 6.9 x 5.3 
cm) an unusual, well limited anechogenic formation 
(structure) 3.5x3 cm showed up inside myometrium, 
along with two minor (1.5 and 1.7 cm) fibromas; endo-
metrium thickness was 4.5 mm, cavum uteri empty 
(Figure). Both ovaries normal.
CT of pelvis showed: “… intensive postcontrast dis-
play of myometrium with a zone of lower density 3.5 
cm which implicates complicated cyst, decomposition 
of tissue...” (Figure). Blood biochemistry finding, and 
tumor markers were normal. As a matter of fact, we 
have never seen such clinical (asymptomatic enlarged 
uterus) combined with unusual ultrasonic and CT dis-
play, (anechogenic, lower density formation within 
myometrium), so we concluded that it is most likely a 
coliquified / liquefied myoma / fibroma. Therefore, ac-
cording to enlarged uterus, age and parity of patient, 
total abdominal hysterectomy and bilateral salpyngo-
oophorectomy was performed.
Pathohistological finding showed endometrial stro-
mal sarcoma. Pathohistological finding: Uterus is en-
larged 10x8x4 cm. In uterine cavity protrudes a tumor 4 
cm in longer diameter, surface of cut is grayish, (Fig-
ure), consistence of tumor is medium solid, in some 
places soft. Tubal tissue did not show any pathohisto-
logical change. In both ovaries some inclusive cysts are 
visible. Exocervical epithelium is regular. In endocervi-
cal area some duplicated subcylindrical reserve cells are 
visible. Endometrial stroma is sturdy with mostly small 
tubular glands, coated with cylindric epithelium. Tumor 
that protrudes into cavity is made of uniformed, oval, 
atypical cells endometrial stroma type, with expressed 
vascularization with small regularly (normally) blood 
vessels. In 1/10 high power fields 1 mitosis is found. 
Immunohistochemistry of tumor cells demonstrate par-
tially positive reaction on CD10, SMA and desmin. Tu-
mor cells in “hot spot” also demonstrate nuclear posi-
tivity on estrogen and progesterone receptors in 90% 
cells. Tumor is partly polypoid, partly in lobulated form, 
partly in finger like projections invades over than ½ of 
myometrium. Clusters of tumor cells are within vascu-
lar spaces (blood vessels) of myometrium. Conclusion: 
histological and immunohistochemical analysis corre-
spond to ESS-low grade. Tumor is limited to the wall of 
corpus uteri (infiltrates ½ of myometrium) and vascular 
infiltration is present.
Figure 2. CT of pelvis showed intensive postcontrast display 
of myometrium
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Since it was a tumor in stage IA, no further therapy 
was necessary. Patient is ordered for first follow-up 
control in 3 months.
Conclusion
Endometrial stromal sarcomas are very rare malig-
nant tumors that make about 0.2% of all uterine malig-
nancies.
A proper preoperative diagnosis is difficult and in 
most cases the diagnosis is confirmed after hysterecto-
my for a presumed benign disease.
Therapy is surgical, and includes hysterectomy and 
salpingo-oophorectomy, with or without lymphadenec-
tomy depending on stage of tumor. Lymph node dissec-
tion provides prognostic information and treatment 
guidance; however, the potential therapeutic value of 
lymph node dissection remains to be determined.
Patients with sarcoma stromal endometrial with ex-
tra-uterine spread of disease, should be submitted to de-
bulking surgery with removal of greatest part of tumor 
possible and subsequently treated with hormone adju-
vant therapy (megestrol acetate 160 mg/day) possibly 
based on knowledge of hormone receptors status, and 
up to regression of disease or toxicity of drug itself.
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SARCOMA STROMALE ENDOMETRIALE  
– RIJEDAK GINEKOLOŠKI TUMOR
Prikaz slučaja i pregled literature
Tonči Visković,1 Mladen Krajcar,1 Martin Gredičak,1 Bruno Grabušić,1  
Rajko Fureš,1 Jadranka Šanjug,1 Tanja Leniček2
Prikaz bolesnice
Ključne riječi: endometralni stromalni sarkom, liječenje
Sažetak. Endometralni stromalni sarkom (ESS) je rijedak tumor. Pojavnost ESS-a je oko 1–2 na milijun žena godišnje. 
Razlikovanje ovog tumora od nekih tumora mekog tkiva kao što su leiomiom, endomatralni polip, karcinosarkom i 
adenomiza je teško, te se dijagnoza najčešće postavlja nakon operacije. Liječenje je kirurško. Histerektomija i obostrana 
adneksektomija su obvezni. Budući su hormonski receptori pozitivni, razmatra se uvođenje adjuvantne hormonske tera-
pije. Zbog rijetkosti ovog tumora ne postoje randomizirane studije, a podatci u literaturi se uglavnom svode na prikaz 
slučaja. Prikazali smo bolesnicu s neobičnim UZV i radiološkim nalazom u uterusu, bez subjektivnih simptoma. Dija-
gnoza endometralnog stromalnog carcinoma je postavljena nakon učinjene histerektomije.
